CL2015002802A1 - Composiciones y métodos para producir cetosis elevada y sostenida - Google Patents

Composiciones y métodos para producir cetosis elevada y sostenida

Info

Publication number
CL2015002802A1
CL2015002802A1 CL2015002802A CL2015002802A CL2015002802A1 CL 2015002802 A1 CL2015002802 A1 CL 2015002802A1 CL 2015002802 A CL2015002802 A CL 2015002802A CL 2015002802 A CL2015002802 A CL 2015002802A CL 2015002802 A1 CL2015002802 A1 CL 2015002802A1
Authority
CL
Chile
Prior art keywords
compositions
methods
produce high
ketosis
sustained ketosis
Prior art date
Application number
CL2015002802A
Other languages
English (en)
Inventor
Agostino Dominic Paul D
Patrick Arnold
Shannon Kesl
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of CL2015002802A1 publication Critical patent/CL2015002802A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UN ACIDO GRASO DE CADENA MEDIA Y AL MENOS UN COMPUESTO DE HIDROXIBUTIRATO; USO PARA ESTIMULAR LA CETOSIS, SUPRIMIR EL APETITO Y ESTIMULAR LA PERDIDA DE PESO EN UN MAMIFERO.
CL2015002802A 2013-03-19 2015-09-17 Composiciones y métodos para producir cetosis elevada y sostenida CL2015002802A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803203P 2013-03-19 2013-03-19
US201461926664P 2014-01-13 2014-01-13

Publications (1)

Publication Number Publication Date
CL2015002802A1 true CL2015002802A1 (es) 2016-05-06

Family

ID=51581503

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015002802A CL2015002802A1 (es) 2013-03-19 2015-09-17 Composiciones y métodos para producir cetosis elevada y sostenida
CL2018000983A CL2018000983A1 (es) 2013-03-19 2018-04-17 Composiciones y métodos para producir cetosis elevada y sostenida (divisional de solicitud n°02802-2015).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018000983A CL2018000983A1 (es) 2013-03-19 2018-04-17 Composiciones y métodos para producir cetosis elevada y sostenida (divisional de solicitud n°02802-2015).

Country Status (20)

Country Link
US (4) US9138420B2 (es)
EP (1) EP2976073B1 (es)
JP (2) JP6491189B2 (es)
KR (2) KR102499654B1 (es)
CN (1) CN105050594B (es)
AU (2) AU2014236004B2 (es)
BR (1) BR112015024186B1 (es)
CA (1) CA2902603C (es)
CL (2) CL2015002802A1 (es)
CR (1) CR20150579A (es)
IL (2) IL241316B (es)
MX (2) MX391526B (es)
MY (1) MY180761A (es)
NZ (1) NZ711433A (es)
PE (1) PE20151949A1 (es)
PH (1) PH12015501966B1 (es)
RU (2) RU2018120938A (es)
SG (2) SG11201506780RA (es)
WO (1) WO2014153416A1 (es)
ZA (1) ZA201506387B (es)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648952B1 (en) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
DK2914251T3 (da) 2012-11-05 2019-11-04 Us Health Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
US20160038456A1 (en) 2013-03-14 2016-02-11 University Of Florida Research Foundation, Incorporated Regulation of cancer using natural compounds and/or diet
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
EP3125904A4 (en) * 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
CN107708688A (zh) * 2015-06-26 2018-02-16 佛罗里达大学研究基金会有限公司 使用天然化合物和/或饮食治疗炎症的方法
US10987340B2 (en) 2015-07-24 2021-04-27 Jesse Alexander Galinski Composition and method for rapidly inducing an endogenous ketosis
US10292952B2 (en) * 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
US20190091189A1 (en) * 2016-03-21 2019-03-28 Csilla Ari D'Agostino Administration of exogenous ketone to lower blood glucose
WO2017165443A1 (en) * 2016-03-21 2017-09-28 Csilla Ari D'agostino Methods of improving motor function using ketone supplementation
US12208074B2 (en) 2016-04-03 2025-01-28 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
CA3021784A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
EP3445358B1 (en) * 2016-04-19 2023-11-15 Keto Patent Group, Inc. Administration of dihydroberberine
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US20220249419A1 (en) * 2016-06-01 2022-08-11 Keto Innovations, Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
WO2017208217A2 (en) 2016-06-01 2017-12-07 Aspi Ip Holder Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
WO2017213999A1 (en) 2016-06-07 2017-12-14 The J. David Gladstone Institutes Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
JP6935994B2 (ja) 2016-08-19 2021-09-15 株式会社明治 ケトン体生成促進用組成物
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
CA3036516A1 (en) * 2016-09-13 2018-03-22 Abbott Laboratories Ketogenic nutritional compositions
WO2018081118A1 (en) * 2016-10-24 2018-05-03 University Of South Florida Delaying latency to seizure by combinations of ketone supplements
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
AU2018230850B2 (en) * 2017-03-08 2023-12-14 Abbott Diabetes Care Inc. Systems, devices, and methods for wellness and nutrition monitoring and management using analyte data
JP6951421B2 (ja) * 2017-03-28 2021-10-20 ロンザ・ソリューションズ・アー・ゲー 水溶性抗菌組成物
US11249087B2 (en) 2017-04-06 2022-02-15 Meiji Co., Ltd. Device for monitoring effective state of ketogenic diet
JP6968624B2 (ja) * 2017-04-06 2021-11-17 株式会社明治 ケトン食摂取量の管理方法
WO2018187852A1 (en) * 2017-04-12 2018-10-18 Cavaleri Franco Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CN107083406B (zh) * 2017-05-27 2021-02-02 浙江华睿生物技术有限公司 (r)-3-羟基丁酸的生产方法
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
WO2019018683A1 (en) 2017-07-21 2019-01-24 Buck Institute For Research On Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF
CN109394745A (zh) * 2017-08-17 2019-03-01 博瑞生物医药（苏州）股份有限公司 一种包含左旋肉碱和β-羟基丁酸化合物的组合物
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US20190119705A1 (en) * 2017-10-20 2019-04-25 KetoneAid Inc. Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2019118624A1 (en) * 2017-12-12 2019-06-20 University Of South Florida Compositions and methods for weight loss maintenance
BR112020013700A2 (pt) * 2018-01-05 2020-12-01 Texas Tech University Office of Research Commercialization métodos para promover perda de gordura, para acelerar perda de gordura, para melhorar performance muscular e para aumentar massa livre de gordura em um indivíduo
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
WO2019152776A1 (en) * 2018-02-01 2019-08-08 Wellstat Therapeutics Corporation Compositions and devices for systemic delivery of uridine
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11484542B2 (en) 2018-05-30 2022-11-01 Adam Slank Specialized tongue spray containing gymnemic acid and exogenous ketones
AU2019280170B2 (en) * 2018-06-07 2024-03-28 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
EP3810120A2 (en) 2018-06-21 2021-04-28 Société des Produits Nestlé S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
US12419852B2 (en) 2018-08-27 2025-09-23 Exerkine Corporation Method for treating lysosomal storage disease
US20200068939A1 (en) * 2018-09-04 2020-03-05 Jho Intellectual Property Holdings Llc Nutritional compositions to increase and sustain blood ketone levels
JP7499259B2 (ja) 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
GB2577723A (en) 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
US20210338613A1 (en) * 2018-10-05 2021-11-04 Dyve Biosciences, Inc. Formulations and methods for transdermal administration of ketones
WO2020092451A1 (en) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
CN109480284A (zh) * 2018-12-05 2019-03-19 上海欣海生物科技有限公司 一种生酮食品及其制备方法
CN113194733A (zh) * 2018-12-18 2021-07-30 雀巢产品有限公司 混合的甘油三酯
CN109734575A (zh) * 2019-01-04 2019-05-10 上海欣海国际贸易有限公司 一种制备3-羟基丁酸氨基酸盐复合物的方法
JP7448555B2 (ja) * 2019-02-11 2024-03-12 アクセス・グローバル・サイエンシーズ・エルエルシー ラセミベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法
ES3033482T3 (en) * 2019-02-11 2025-08-04 Axcess Global Sciences Llc S-beta-hydroxybutyrate compounds and compositions enriched with s-enantiomer
CA3129411A1 (en) * 2019-02-11 2020-08-20 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt-acid compositions and methods of use
KR20210135551A (ko) * 2019-03-04 2021-11-15 세레신 인코포레이티드 개선된 생체이용률을 갖는 중쇄 트리글리세라이드 제제 및 이와 관련된 방법
CA3129569A1 (en) 2019-03-14 2020-09-17 Thomas Weimbs Methods and compositions for supporting renal health
JP7281927B2 (ja) * 2019-03-14 2023-05-26 大阪瓦斯株式会社 心拍数低減剤
BR112021016338A2 (pt) * 2019-03-22 2021-10-26 Société des Produits Nestlé S.A. Métodos que usam triglicerídeos de cadeia média administrados antes de uma refeição para diminuir a glicose pós-prandial da refeição
AU2020246928B2 (en) * 2019-03-22 2025-05-15 Société des Produits Nestlé S.A. Methods using administration of medium chain triglycerides (MCT) prior to a meal to increase ketone production from the MCTs
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
EP3956282A1 (de) * 2019-06-12 2022-02-23 IOI Oleo GmbH Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11915605B2 (en) 2019-10-17 2024-02-27 Nicolas Tzenios Ketogenic diet recommendation to a user based on a blood low-density lipoprotein (LDL) level and a blood C-reactive protein level and/or a blood erythrocyte sedimentation rate (ESR) thereof
US20230172891A1 (en) * 2020-01-23 2023-06-08 University Of South Florida Prevention and treatment of effects of aging and age-associated disorders with ketone supplementation
EP4114203A1 (en) 2020-03-05 2023-01-11 VitaNav, Inc. COMPOSITION OF (D)-ß-HYDROXYBUTYRIC ACID, (D)-ß-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT
US12396974B2 (en) 2020-03-27 2025-08-26 KetoneAid Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
EP4164407A4 (en) * 2020-06-14 2024-08-28 L-Nutra Inc. BAR/DRINK FOR INTERMITTENT FASTING THAT MAINTAINS AND PROLONGS THE FASTING STATE
CA3188646A1 (en) * 2020-07-02 2022-01-06 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
US12186297B2 (en) * 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN112137115A (zh) * 2020-09-25 2020-12-29 深圳市捷利康生物科技有限公司 具有增强免疫力功效的生酮营养粉及其制备方法
US20240180891A1 (en) * 2020-12-22 2024-06-06 Buck Institute For Research On Aging Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
CA3159213A1 (en) * 2021-04-16 2022-10-16 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Low-lead and low-arsenic beta-hydroxybutyrate salts and methods for producing the same
US20240197659A1 (en) * 2021-04-26 2024-06-20 University Of South Florida Methods for treating symptoms of kabuki syndrome
RU2769242C1 (ru) * 2021-06-16 2022-03-29 Александр Владимирович Чемоданов Кетогенная композиция
EP4363599A1 (en) 2021-06-28 2024-05-08 PHB Industrial S.A. Methods to produce therapeutic formulations comprising hydroxybutirate and hydroxyvalerate, therapeutic formulations and uses thereof
US12226239B2 (en) 2021-09-15 2025-02-18 Lingo Sensing Technology Unlimited Company Systems, devices, and methods for applications for communication with ketone sensors
CN118382365A (zh) * 2021-12-14 2024-07-23 三得利控股株式会社 含有3羟基丁酸及低级脂肪族醇的饮料及呈味改善方法
AU2022411334A1 (en) * 2021-12-14 2024-06-13 Suntory Holdings Limited Carbonated beverage, and method for enhancing sense of carbonation of beverage
CN114306308A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有酮酯的营养补充剂及其应用
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
JP7223193B1 (ja) 2022-05-26 2023-02-15 大阪瓦斯株式会社 内臓脂肪低減剤およびその用途
CN115192603B (zh) * 2022-07-06 2023-04-21 西北农林科技大学 锂盐在制备防治奶牛酮病制剂中的应用
CN115251375A (zh) * 2022-07-11 2022-11-01 珠海麦得发生物科技股份有限公司 一种(r)-3-羟基丁酸生酮产品及其制备方法
US12059398B2 (en) 2022-08-26 2024-08-13 Health Via Modern Nutrition Inc. Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis
CN121889495A (zh) 2023-09-05 2026-04-17 加利福尼亚大学董事会 氧化β-羟基丁酸盐(BHB)的酶、使用酶的测试试纸条和传感器
WO2026037224A1 (zh) * 2024-08-14 2026-02-19 南京纽邦生物科技有限公司 提高或维持酮体水平、改善代谢功能的方法和组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803141L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
JPH1160434A (ja) 1997-08-12 1999-03-02 Kanebo Ltd 皮膚老化防止化粧料
DE69922206T2 (de) 1998-07-22 2005-11-24 Metabolix, Inc., Cambridge Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
DK1123094T3 (da) 1998-09-15 2007-08-20 Btg Int Ltd Terapeutiske præparater (II)
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
WO2007115282A2 (en) * 2006-04-03 2007-10-11 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
AU2001257451A1 (en) 2000-05-01 2001-11-12 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US6613356B1 (en) 2000-10-10 2003-09-02 Victor Vlahakos Weight loss medication and method
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US8158184B2 (en) * 2004-03-08 2012-04-17 Bunge Oils, Inc. Structured lipid containing compositions and methods with health and nutrition promoting characteristics
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
WO2008128095A1 (en) * 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
EP2240017B1 (en) * 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output

Also Published As

Publication number Publication date
MX2015013312A (es) 2016-06-07
CA2902603C (en) 2021-03-02
PH12015501966A1 (en) 2016-01-11
IL259502A (en) 2018-07-31
HK1216847A1 (zh) 2016-12-09
KR20220011785A (ko) 2022-01-28
EP2976073B1 (en) 2019-08-28
AU2019200511A1 (en) 2019-02-14
CN105050594A (zh) 2015-11-11
BR112015024186B1 (pt) 2023-05-09
PH12015501966B1 (en) 2016-01-11
RU2018120938A3 (es) 2019-04-04
US20170266148A1 (en) 2017-09-21
RU2018120938A (ru) 2018-11-06
PE20151949A1 (es) 2016-01-05
EP2976073A1 (en) 2016-01-27
CA2902603A1 (en) 2014-09-25
US20160067207A1 (en) 2016-03-10
US9138420B2 (en) 2015-09-22
EP2976073A4 (en) 2017-02-22
JP6491189B2 (ja) 2019-03-27
JP2016514725A (ja) 2016-05-23
SG11201506780RA (en) 2015-10-29
NZ711433A (en) 2017-03-31
ZA201506387B (en) 2017-08-30
US20200268701A1 (en) 2020-08-27
BR112015024186A2 (pt) 2017-07-18
MY180761A (en) 2020-12-08
SG10201808690PA (en) 2018-11-29
CR20150579A (es) 2016-01-04
KR20150130312A (ko) 2015-11-23
RU2659386C2 (ru) 2018-06-29
AU2014236004B2 (en) 2018-10-25
MX2019010248A (es) 2019-10-09
RU2015136190A (ru) 2017-03-10
US9675577B2 (en) 2017-06-13
CL2018000983A1 (es) 2018-10-12
AU2014236004A1 (en) 2015-09-10
US20140350105A1 (en) 2014-11-27
CN105050594B (zh) 2019-11-12
KR102499654B1 (ko) 2023-02-13
US10646462B2 (en) 2020-05-12
WO2014153416A1 (en) 2014-09-25
MX391526B (es) 2025-03-21
IL241316A0 (en) 2015-11-30
IL259502B (en) 2019-09-26
JP2019031578A (ja) 2019-02-28
MX371259B (es) 2020-01-23
IL241316B (en) 2018-08-30

Similar Documents

Publication Publication Date Title
CL2015002802A1 (es) Composiciones y métodos para producir cetosis elevada y sostenida
AR096897A1 (es) Transferencia de peso en un implemento con control de realimentación
CL2016000508A1 (es) Compuestos derivados de (2-metil-3-fenilfenil)metoxi sustituidos, inhibidores de la interacción pd-1/proteína pd-l1/proteína; composición farmacéutica que los comprende; y su uso para tratar una enfermedad infecciosa o cáncer.
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
CL2012002859A1 (es) Metodo para reducir el peso de un sujeto que comprende el uso de un modulador antioxidante de la inflamacion.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
GT201400111A (es) Triazolopiridinas sustituidas
CL2016000017A1 (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
CL2013003576A1 (es) Composicion farmaceutica que comprende nilotinib; forma de dosificacion que comprende nilotinib; metodo para preparar nilotinib; metodo para preparar la forma de dosificacion; y uso de un acido organico para aumentar la biodisponibilidad de nilotinib y para suprimir el efecto del alimento asociado a la composicion farmaceutica.
EP2997246A4 (en) Piston having combustion bowl shaped to balance combustion efficiency and emission properties
CR20130680A (es) Métodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales i
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
MX380453B (es) Metodo para mejorar el valor nutricional de pienso para animales.
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
UY34751A (es) ?composición de pienso para reducir la metanogénesis en rumiantes?
NI201400042A (es) 2 - tiopirimidinonas
AR092566A1 (es) Composiciones grasas para mantener una palatabilidad de alimentos para animales domesticos en el tiempo
AR100306A1 (es) Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
NI201600006A (es) Pirazolo-piridinaminas sustituidas
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
CL2014001834A1 (es) Uso de semilla de palta con el fin de obtener mediante presion mecanica aceite de palta enriquecido en alquil polioles, donde dichas semillas representan el 10 al 50% en peso en relacion con el peso total de la palta utilizada; metodo para obtener aceite de palta; y aceite de palta enriquecido; uso de aceite de palta; e insaponificable de palta.
MX388970B (es) Formulaciones para estabilizar la humedad en alimentos musculares.
CR20160066A (es) Compuestos y métodos para mejorar el rendimiento de una planta